CASI Pharma (NASDAQ: CASI) reported Q3 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $7.54 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.